Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 9/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351037 | 0.98 | PTGS2 (0.49) | MAP2PTGS2MAPTALOX15MAPK1 | |
| SCHEMBL2344579 | 0.97 | PTGS2 (0.51) | MAP2PTGS2MAPTALOX15MAPK1 | |
| SCHEMBL2346319 | 0.91 | MAP2 (0.46) | MAP2PTGS2MAPTALOX15MAPK1 | |
| SCHEMBL2344047 | 0.90 | MAP2 (0.48) | MAP2PTGS2MAPTALOX15MAPK1 | |
| SCHEMBL2351150 | 0.87 | MAP2 (0.45) | MAP2PTGS2MAPTALOX15MAPK1 | |
| SCHEMBL3616584 | 0.86 | TDP1 (0.42) | MAPTMAPK1SIRT1TDP1BRAF | |
| SCHEMBL2346920 | 0.86 | MAP2 (0.45) | MAP2PTGS2MAPTALOX15MAPK1 | |
| SCHEMBL14282084 | 0.86 | MAP2 (0.44) | MAP2PTGS2MAPK1SIRT1 | |
| SCHEMBL3609243 | 0.84 | HTT (0.44) | MAPTALOX15MAPK1SMN1; SMN2SIRT1 | |
| SCHEMBL3602148 | 0.83 | HTT (0.46) | MAPTALOX15MAPK1SIRT1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | claimed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | claimed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | claimed |
| EP-1899340-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | claimed |
| WO-2007002368-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | claimed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008295-B2 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20080008708-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060128783-A1 | Tyrosine kinase inhibitors | DINSMORE CHRISTOPHER J | 2006-06-15 | — | — | US | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | MAP2 2470/4885PTGS2 1715/4885MAPT 716/4885 |
| US-20060128783-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | MAP2 721/4885PTGS2 1578/4885MAPT 2487/4885 |
| US-20080008708-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, JAK2 | MAP2 721/4885PTGS2 1578/4885MAPT 2487/4885 |
| US-20100041652-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, JAK2 | MAP2 721/4885PTGS2 1578/4885MAPT 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.